Fractyl Health Presents New Clinical Results From German Real-World Registry Showing Meaningful And Sustained Weight Loss For At Least 1-Year After A Single Revita Endoscopic Procedure
Portfolio Pulse from Benzinga Newsdesk
Fractyl Health, Inc. (NASDAQ:GUTS) announced new clinical results from its German Real-World Registry, showing significant weight loss and blood sugar reduction in patients with obesity and Type 2 Diabetes after a single Revita endoscopic procedure. The results indicate a median weight loss of nearly 13% and a substantial decrease in HbA1c levels over 12 months.
August 08, 2024 | 12:08 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Fractyl Health, Inc. (NASDAQ:GUTS) reported promising clinical results from its German Real-World Registry, showing significant weight loss and blood sugar reduction in patients with obesity and Type 2 Diabetes after a single Revita endoscopic procedure.
The positive clinical results from the German Real-World Registry demonstrate the effectiveness of Fractyl Health's Revita procedure in achieving significant weight loss and blood sugar reduction. This could boost investor confidence and positively impact the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100